One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis

被引：20
作者：
Zéphir, H
de Seze, J
Dujardin, K
Dubois, G
Cabaret, M
Bouillaguet, S
Ferriby, D
Stojkovic, T
Vermersch, P
机构：
[1] Univ Lille 2, Hop Roger Salengro, Dept Neurol, F-59047 Lille, France
[2] Univ Lille 3, Dept Psychol, F-59653 Villeneuve Dascq, France
[3] CHR, F-59047 Lille, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2005年 / 11卷 / 03期
关键词：
cognitive function; cyclophosphamide; merhylprednisolone; progressive multiple sclerosis;
D O I：
10.1191/1352458505ms1172sr
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
We conducted an evaluation of changes in cognition in progressive multiple sclerosis (MS) patients receiving monthly intravenously pulse of cyclophosphamide (700 mg/m(2)) with methylprednisolone (1 g). Twenty-eight consecutive progressive MS patients (10 primary progressive, 18 secondary progressive MS) were evaluated before and after six and 12 months of treatment. The WAIS-R score, memory and executive functions were evaluated Under treatment we found a significant improvement in global cognitive efficiency, encoding abilities, planning abilities and inhibition after six and 12 months. However mechanisms of action of the positive effect of these anti-inflammatory and immunosuppressive treatments on cognition remain unclear.
引用
收藏
页码：360 / 363
页数：4
相关论文
共 11 条
[1]   Effect of interferon-beta-1b on cognitive functions in multiple sclerosis [J].
Barak, Y ;
Achiron, A .
EUROPEAN NEUROLOGY, 2002, 47 (01) :11-14
[2]   IDENTIFYING MULTIPLE-SCLEROSIS PATIENTS WITH MILD OR GLOBAL COGNITIVE IMPAIRMENT USING THE SCREENING EXAMINATION FOR COGNITIVE IMPAIRMENT (SEFCI) [J].
BEATTY, WW ;
PAUL, RH ;
WILBANKS, SL ;
HAMES, KA ;
BLANCO, CR ;
GOODKIN, DE .
NEUROLOGY, 1995, 45 (04) :718-723
[3]  
Fischer JS, 2000, ANN NEUROL, V48, P885, DOI 10.1002/1531-8249(200012)48:6<885::AID-ANA9>3.0.CO
[4]  
2-1
[5]   Interferon β therapy for multiple sclerosis [J].
Goodkin, DE .
LANCET, 1998, 352 (9139) :1486-1487
[6]   The progress of cognitive decline in multiple sclerosis - A controlled 3-year follow-up [J].
Kujala, P ;
Portin, R ;
Ruutiainen, J .
BRAIN, 1997, 120 :289-297
[7]   Changes of the MS functional composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis [J].
Patzold, T ;
Schwengelbeck, M ;
Ossege, LM ;
Malin, JP ;
Sindern, E .
ACTA NEUROLOGICA SCANDINAVICA, 2002, 105 (03) :164-168
[8]   NEW DIAGNOSTIC-CRITERIA FOR MULTIPLE-SCLEROSIS - GUIDELINES FOR RESEARCH PROTOCOLS [J].
POSER, CM ;
PATY, DW ;
SCHEINBERG, L ;
MCDONALD, WI ;
DAVIS, FA ;
EBERS, GC ;
JOHNSON, KP ;
SIBLEY, WA ;
SILBERBERG, DH ;
TOURTELLOTTE, WW .
ANNALS OF NEUROLOGY, 1983, 13 (03) :227-231
[9]   Primary progressive multiple sclerosis [J].
Thompson, AJ ;
Polman, CH ;
Miller, DH ;
McDonald, WI ;
Brochet, B ;
Filippi, M ;
Montalban, X ;
DeSa, J .
BRAIN, 1997, 120 :1085-1096
[10]   Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects [J].
Weiner, HL ;
Cohen, JA .
MULTIPLE SCLEROSIS JOURNAL, 2002, 8 (02) :142-154
12